Zhejiang Ausun Pharmaceutical Dividends and Buybacks
Dividend criteria checks 3/6
Zhejiang Ausun Pharmaceutical is a dividend paying company with a current yield of 1.11% that is well covered by earnings.
Key information
1.1%
Dividend yield
0%
Buyback Yield
| Total Shareholder Yield | 1.1% |
| Future Dividend Yield | 1.1% |
| Dividend Growth | 22.8% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | CN¥0.0921 |
| Payout ratio | 29% |
Recent dividend and buyback updates
No updates
Recent updates
There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise
Oct 08
Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet
Jul 31Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified
Mar 06Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 603229 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 603229's dividend payments have increased, but the company has only paid a dividend for 6 years.
Dividend Yield vs Market
| Zhejiang Ausun Pharmaceutical Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (603229) | 1.1% |
| Market Bottom 25% (CN) | 0.5% |
| Market Top 25% (CN) | 2.1% |
| Industry Average (Pharmaceuticals) | 1.7% |
| Analyst forecast (603229) (up to 3 years) | 1.1% |
Notable Dividend: 603229's dividend (1.11%) is higher than the bottom 25% of dividend payers in the CN market (0.55%).
High Dividend: 603229's dividend (1.11%) is low compared to the top 25% of dividend payers in the CN market (2.17%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (29.1%), 603229's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (56.6%), 603229's dividend payments are covered by cash flows.